Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Searle Receives Approval to Produce Arthritis Medicine in Pakistan

Searle Company Limited obtains approval for ADALIMUMAB, the first locally manufactured Monoclonal antibody (mAB) in Pakistan, developed in collaboration with BioRay Biopharmaceuticals. This strategic move aims to provide high-quality, affordable biotechnology medicines to patients, diversify the product portfolio, and enhance shareholder value. ADALIMUMAB, a breakthrough antibody, will address various health conditions and contribute to Searle’s commitment to healthcare innovation.

Searle Receives Approval to Produce Arthritis Medicine in Pakistan

The Searle Company Limited has gotten permission from the Drug Regulatory Authority of Pakistan (DRAP) for a new medicine called ADALIMUMAB. This medicine was made in partnership with BioRay Biopharmaceuticals Co. Limited in China. The company shared this news with the Pakistan Stock Exchange on Thursday.

This is a big deal because ADALIMUMAB is the first Monoclonal antibody (mAB) made locally in Pakistan. The company plans to release ADALIMUMAB to the public in the next 3-6 months. They want to make good quality medicines that people can afford. The company says this is part of their plan to offer a variety of products and improve their earnings and value for shareholders.

Searle will be in charge of selling ADALIMUMAB in Pakistan. This partnership will help meet the medical needs of patients and spread BioRay’s ADALIMUMAB around the world. The medicine was first approved in China in 2019. It’s a special antibody that can stick to certain molecules in the body and stop them from causing harm.

Wahaj Ali Emerges as the Leading Asian Celebrity from Pakistan in 2023

ADALIMUMAB is used to treat different health issues like arthritis, psoriasis, Crohn’s disease, and more. Searle is a company that makes medicines and other products. Its parent company, International Brands (Private) Limited, owns 56.32 percent of Searle.

Leave a Reply

Your email address will not be published. Required fields are marked *